SEC Tracker
Get the app

LENZ Therapeutics LENZ

LENZ Therapeutics Therapeutics reports $30.97 million net loss for Q3 2026

Form
10-Q
Filed
Importance
Notable
  1. Revenue of $3.38 million for the three months ended Sep 30, 2026
  2. Net loss of $30.97 million for the three months ended Sep 30, 2026
  3. Cash and equivalents of $30.55 million as of Sep 30, 2026

Written from the 10-Q on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when LENZ Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

0 of 6 claims matched the filing text.

Not found in the filing text

  • For the quarter ended September 30, 2026, LENZ Therapeutics, Inc. reported: Revenue $3.4 million.
  • Net income -$31.0 million.
  • Gross margin 86.6%.
  • Operating margin -972.8%.
  • Net margin -915.2%.
  • Revenue change from a year earlier -72.9%.

Similar companies

Same SIC code (2836) and public float $300M to $2B, nearest public float first, as each company reports it on its annual report cover.

  1. ImmunityBio IBRX public float $690M, Jun 30, 2025
  2. Vir Biotechnology VIR public float $689M, Jun 30, 2025
  3. Anavex Life Sciences AVXL public float $708M, Mar 31, 2025, over 18 months old
  4. Relay Therapeutics RLAY public float $586M, Jun 30, 2025
  5. Ginkgo Bioworks Holdings DNA public float $553M, Jun 28, 2025